Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2323 • ACR Convergence 2023
An Electronic Health Record-Based Algorithm for Predicting Systemic Lupus Erythematosus Flares: Integrating Clinical Factors and Social Determinants of Health
Yu Huang¹, Lixia Yao², zhengkang Fan³, Jingchuan Guo¹ and Jiang Bian¹, ¹University of Florida, Gainesville, FL, ²Polygon Health Analytics LLC, Chalfont, PA, ³University of Florida, Gainsville, FL
Background/Purpose: Systemic lupus erythematosus (SLE) has a relapsing-remitting course, with patients experiencing disease activity flares over time. Flares and prolonged disease activity are associated with…
Abstract Number: 2342 • ACR Convergence 2023
Modulation of B Cell and Interferon Pathways by Ianalumab in Patients with Systemic Lupus Erythematosus: Findings from a Phase 2 Clinical Trial
Aida Santos da Costa¹, Thomas Dörner², Andrea Grioni¹, Alexandre Avrameas¹, Ulrike Sommer¹, Rainer Hillenbrand¹, Valeria De Luca¹, Enrico Ferrero¹, Andre Nogueira da Costa¹, Isabelle Isnardi¹ and Stephen J Oliver¹, ¹Novartis Pharma AG, Basel, Switzerland, ²Department of Medicine, Rheumatology and Clinical Immunology, Charité Universitätsmedizin and Deutsches Rheumaforschungszentrum, Berlin, Germany
Background/Purpose: Ianalumab (VAY736) is an afucosylated monoclonal antibody targeting the B cell activating factor receptor (BAFFR) that depletes B cells via enhanced antibody dependent cellular…
Abstract Number: 2453 • ACR Convergence 2023
Development of a Hydroxychloroquine Retinopathy Prediction Score
April Jorge¹, Ronald Melles², Baijun Zhou¹, Yuqing Zhang³ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Kaiser Permanente Northern California, Redwood City, CA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Hydroxychloroquine (HCQ) is an important medication for SLE and other rheumatic diseases, but its major adverse event is HCQ retinopathy. Weight-based HCQ dose is…
Abstract Number: 2527 • ACR Convergence 2023
Risk Factors for Bone Loss in Systemic Lupus Erythematosus
Nima Madanchi¹, Andrea Fava², Daniel Goldman³, Larry Magder⁴ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, MD
Background/Purpose: Osteoporotic fractures are the most common damage item from the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index. Previous…
Abstract Number: PP07 • ACR Convergence 2023
How “Coming Out” About My Lupus Diagnosis Allowed Me to Connect With Patients, Get Involved With Research, and Spread Awareness
Jamie Chieh Lo, School of Medicine, I-Shou University, Keelung, Taiwan
Background/Purpose: Ever since I started medical school, I have been advised to not talk about my experiences with SLE. Family, friends, and even professors have…
Abstract Number: 0060 • ACR Convergence 2023
Serpin B1 Modulation of Immune Complex-Mediated Neutrophil Activation and NET-formation Requires Its Chymotrypsin-like Inhibitory Activity
Ting Wang¹, Philip Pemberton² and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Redd Pharmaceuticals, Belmont, CA
Background/Purpose: Autoantibody-antigen complex-driven formation of neutrophil extracellular traps (NETs) is a major contributing factor to the pathophysiology and clinical manifestations of many different autoimmune diseases…
Abstract Number: 0174 • ACR Convergence 2023
Evaluation of Healthcare Utilization in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Jean Park, W. Cliff Rutter, Elisea Avalos-Reyes, Chen Liu, Will Cavers, Dorothea Verbrugge and Kjel Johnson, CVS Health, Woonsocket, RI
Background/Purpose: Healthcare utilization is increasing among patients with rheumatic diseases. While several studies have assessed healthcare utilization in rheumatoid arthritis (RA) patients, few studies have…
Abstract Number: 0261 • ACR Convergence 2023
Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results
April W. Armstrong¹, Mark Lebwohl², Richard B. Warren³, Howard Sofen⁴, Shinichi Imafuku⁵, Mamitaro Ohtsuki⁶, Lynda Spelman⁷, Thierry Passeron⁸, Kim A Papp⁹, Renata M. Kisa¹⁰, Victoria Berger¹⁰, Eleni Vritzali¹¹, Kim Hoyt¹⁰, Matthew J. Colombo¹⁰, Subhashis Banerjee¹⁰, Bruce Strober¹², Diamant Thaçi¹³ and Andrew Blauvelt¹⁴, ¹Keck School of Medicine of University of Southern California, Los Angeles, CA, ²Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ³Dermatology Centre, Northern Care Alliance NHS Foundation Trust; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴University of California Los Angeles School of Medicine and Dermatology Research Associates, Los Angeles, CA, ⁵Fukuoka University Faculty of Medicine, Fukuoka, Japan, ⁶Jichi Medical University, Tochigi, Japan, ⁷Veracity Clinical Research, Brisbane, Australia, ⁸Université Côte d’Azur, University Hospital of Nice, Nice, France, ⁹Alliance Clinical Research and Probity Medical Research, Waterloo, and University of Toronto, Toronto, ON, Canada, ¹⁰Bristol Myers Squibb, Princeton, NJ, ¹¹Bristol Myers Squibb, Sissach, Switzerland, ¹²Yale University, New Haven, CT, ¹³Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ¹⁴Oregon Medical Research Center, Portland, OR
Background/Purpose: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in multiple countries for the treatment of adults plaque psoriasis. Deucravacitinib was…
Abstract Number: 0550 • ACR Convergence 2023
Harnessing Machine Learning to Predict Neuropsychiatric Events in Systemic Lupus Erythematosus
Nursen Cetrez¹, Julius Lindblom¹, Raffaele Da Mutten², Dionysis Nikolopoulos² and Ioannis Parodis¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) is linked to increased morbidity, mortality, and adverse health-related quality of life. Early disease, a history of NPSLE, aPL…
Abstract Number: 0567 • ACR Convergence 2023
N-Terminal Pro-Brain Natriuretic Peptide Correlates Strongly with Cardiovascular Damage in Systemic Lupus Erythematous (SLE): A Cross-sectional Study
Karim Sacre¹, Evelyne Vinet², Christian Pineau², Arielle Mendel³, Fares Kalache³, Louis Pierre Grenier³, Thao Huynh³ and Sasha Bernatsky⁴, ¹Université Paris Cité, Paris, France, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Cardiovascular (CV) disease represents the leading cause of death in SLE. Traditional risk factors are less accurate at identifying cardiovascular risk in SLE than…
Abstract Number: 0585 • ACR Convergence 2023
The Impact of Impaired Vagus Nerve Activity and Transcutaneous Vagus Nerve Stimulation (tVNS) on Arterial Stiffness in Systemic Lupus Erythematosus (SLE)
Tobias Schmidt¹, Christina Brock², Jesper Fleischer³, Søren Jacobsen¹ and Amanda Hempel Zinglersen¹, ¹Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ²Department of Gastroenterology and Hepatology, Aalborg University Hospital and Clinical Institute, Aalborg, Denmark, ³Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease with an increased risk of atherosclerosis. The development of atherosclerosis in SLE cannot be…
Abstract Number: 001 • 2023 Pediatric Rheumatology Symposium
Serious Infections Among Children with Systemic Lupus Erythematosus in the Pediatric Health Information System
Jordan Roberts, Anna Faino, Mersine Bryan, Jonathan Cogen and Esi Morgan, Seattle Children's Hospital, Seattle, WA
Background/Purpose: High rates of serious infection have beenreported in pediatric systemic lupus erythematosus (pSLE), but modern care practices including pneumococcal vaccination, changing corticosteroid use, and…
Abstract Number: 087 • 2023 Pediatric Rheumatology Symposium
Delays in Care, Declines in Health, and Food Insecurity in Pediatric Systemic Lupus Erythematosus Patients During the COVID-19 Pandemic
Rebecca Hetrick¹, Maria Pereira² and Marietta De Guzman³, ¹Indiana University School of Medicine, Indianapolis, IN, ²Baylor College of Medicine, Houston, TX, ³Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: The COVID-19 pandemic created dramatic societal disruptions. Social distancing and measures to reduce disease spread rapidly reshaped healthcare delivery. Recognizing the burden of frequent…
Abstract Number: 002 • 2023 Pediatric Rheumatology Symposium
Re-analysis of the APPLE (Atherosclerosis Prevention in Paediatric Lupus Erythematosus) Trial Identifies Novel Determinants of Patient Heterogeneity and a Distinct Lipid Metabolomic Signature of Atherosclerosis Progression
Coziana Ciurtin¹, Junjie Peng¹, Pierre Donnes¹, Stacy Ardoin², Laura Schanberg³, Laura Lewandowski⁴, George A Robinson¹ and Elizabeth Jury¹, ¹University College London, London, United Kingdom, ²Nationwide Children's Hospital, Columbus, OH, ³Duke University Medical Center, Durham, NC, ⁴NIAMS, NIH, Bethesda, MD
Background/Purpose: Juvenile-onset systemic lupus erythematosus (JSLE) is associated with chronic inflammation and increased risk of atherosclerosis. The APPLE trial was a randomised, placebo-controlled trial of…
Abstract Number: 091 • 2023 Pediatric Rheumatology Symposium
Achieving Remission in Childhood-onset Systemic Lupus Erythematosus: Rapid Implementation of an EMR-integrated Dashboard to Measure Disease Activity and Remission Rates
Kaleo Ede¹, Nikita Goswami², Elisa Wershba², Michael Shishov², Samantha Casselman², Pierina Ortiz² and Vinay Vaidya², ¹Phoenix Children's Hosptial; University of Arizona College of Medicine- Phoenix, Phoenix, AZ, ²Phoenix Children's Hospital, Phoenix, AZ
Background/Purpose: Children with childhood-onset systemic lupus erythematosus (cSLE) experience more severe disease than their adult counterparts, in addition to high rates of clinical depressive symptoms…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.